Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Crucell, DSM License Line to AbGenomics | Contract Pharma

What are you searching for?

Sign in
Breaking News

Crucell, DSM License Line to AbGenomics

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Crucell N.V. and DSM Biologics have signed a PER.C6 research license agreement with the Taiwan-based AbGenomics Corp. AbGenomics intends to use the PER.C6 cell line for its R&D and early clinical studies of monoclonal antibodies.

“The unique characteristics of the PER.C6 technology as a human cell line combined with the short timeline involved in producing clinical material along with the technology’s robustness undoubtedly makes our choice for PER.C6 highly imperative,” said Shih-Yao Lin, Ph.D., president of AbGenomics.

Under the terms of the agreement, AbGenomics will make license payments and annual maintenance fees in exchange for certain rights. Financial details were not disclosed.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters